Pharmaceutical

pharma-news-for-neurocrine-astrazeneca-immunovant

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Neurocrine Signs Deal to Acquire Soleno Therapeutics; AstraZeneca Shares Favorable Results from EMERALD-3 Study in Liver Cancer; Immunovant Presents Phase 3 Clinical Data for Batoclimab in TED; Alto Neuroscience Shares Topline Findings from Phase 2 ALTO-101 Study and Pipeline Updates; ORIC Positions Rinzimetostat for Phase 3 Success with Optimized Dosing Strategy

Explore More...
achondroplasia-treatment-landscape

Achondroplasia Treatment: Emerging Therapies, Pathway Strategies, and Market Outlook

pharma-news-for-sarepta-merck-bms

Sarepta Secures FDA Approval of Revised Prescribing Information for ELEVIDYS; Merck to Acquire Cidara Therapeutics; BMS & J&J Halt Milvexian Phase III in ACS After Interim Review; Kura Oncology & Kyowa Kirin Win FDA Green Light for KOMZIFTI in NPM1-Mutated AML; Novartis’ Phase III KLU156 (GanLum) Trial Hits Primary Endpoint

tslp-inhibitors-landscape

TSLP Inhibitors: The New Frontier in Treating Type 2 Inflammatory Diseases

graves-orbitopathy-treatment-landscape

Biologics and The Battle For Sight: How A New Wave of Therapies is Transforming Graves’ Orbitopathy Treatment

pharma-news-for-cogent-biosciences-anaptys-eledon

Cogent Biosciences’ Bezuclastinib Phase 3 PEAK Trial Positive Results for GIST; Domain Therapeutics Begins Phase I/II Trial of CCR8 Inhibitor DT-7012 in Solid Tumors; Anaptys Reports Negative Phase 2 Outcomes for Rosnilimab in Ulcerative Colitis; QOL Medical Strikes Deal to Acquire Evoke Pharma for $11 Cash Per Share; Eledon Pharmaceuticals, Inc. Unveils Phase 2 BESTOW Trial Data for Tegoprubart in Kidney Transplant Rejection Prevention at ASN Kidney Week 2025

kygevvi-for-tk2d

UCB’s KYGEVVI Approval: A Breakthrough for Thymidine Kinase 2 Deficiency

bayer-lynkuet-for-vms

Bayer’s Lynkuet Ushers in New Class of Therapies for Menopause

Most Promising Therapies in the Parkinson’s Disease Treatment Market

Most Promising Therapies in the Parkinson’s Disease Treatment Market

DNA Sequencing Market Insights

Decoding the $60 Billion Future: Top Trends Driving the DNA Sequencing Market to 2032

Nanomedicine Transforming Healthcare Market Dynamics

Nanomedicine’s Impact: Transforming the Future of Healthcare Industry Dynamics

lupus-nephritis-drugs

New Lupus Nephritis Drugs on the Horizon: 6 Promising Therapies Eyeing Newly Approved GAZYVA’s Market Space

novo-metsera-acquisition

Pharma Rivalry Intensifies: Novo Nordisk Looks to Wrest Metsera from Pfizer

pharma-news-for-novartis-gsk-syndax

Syndax Pharmaceuticals Receives FDA Approval for REVUFORJ; FDA Approves BLENREP for Adults with Relapsed/Refractory Multiple Myeloma; Novartis to Acquire Avidity for $12 Billion; BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study; Eli Lilly to Acquire Adverum Biotechnologies

gazyva-for-lupus-nephritis-treatment

Roche’s GAZYVA Extends Indications Into Lupus, Strengthening Immunology Pipeline

emerging-chronic-pruritus-drugs

4 Investigational Chronic Pruritus Drugs Shaping the Treatment Landscape

pharma-news-for-roche-astrazeneca-replimune

FDA Approves Genentech’s GAZYVA for Lupus Nephritis; Glaukos’ EPIOXA Wins FDA Approval for Keratoconus Treatment; FDA Accepts Replimune’s RP1 BLA Resubmission for Advanced Melanoma; Cogent’s Bezuclastinib Earns FDA Breakthrough Therapy for SM-AHN; Amgen’s TEZSPIRE Gets FDA Nod for Chronic Rhinosinusitis with Nasal Polyps

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader